“Regulatory Predictability” Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says

FDA's new leadership should focus on improving "regulatory predictability" for orphan drug development, Social Security Administration Commissioner Michael Astrue said during a discussion of orphan drug policy sponsored by Shire Pharmaceuticals, the National Chamber Foundation and the U.S. Chamber of Conference in Washington, D.C. June 4